# A Trial of Radiotherapy and Durvalumab in DLBCL and FL

> **NCT03610061** · PHASE1 · COMPLETED · sponsor: **Austin Health** · enrollment: 34 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma

## Interventions

- **DRUG:** Durvalumab
- **RADIATION:** Radiotherapy
- **RADIATION:** Radiotherapy (cohort 6 only)

## Key facts

- **NCT ID:** NCT03610061
- **Lead sponsor:** Austin Health
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-01
- **Primary completion:** 2023-04-05
- **Final completion:** 2024-04-08
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-04-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03610061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03610061, "A Trial of Radiotherapy and Durvalumab in DLBCL and FL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03610061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*